论文部分内容阅读
153例初治涂阳肺结核患者随机分组,1981年R_Ⅰ组2SHR/7HR,D_Ⅰ组2SHD/7HD;1983年R_Ⅱ组9HRE,D_Ⅱ组9HDE,133例治满疗程。R_Ⅰ、D_Ⅰ组近期疗效相仿,但远期率效D组较R组差,这可能与使用利福定的晶型及剂型有关。1983年R组、D组在痰菌阴转率、空洞关闭率、病灶总有效率均相仿,且停药随访2年的痰菌复发率亦无显著差异。表明利福定需选用有效晶型和合适剂型方可在相当利福平常规治疗剂量1/2的用量下取得相似的疗效,且副反应少,治疗费用低。
153 cases of newly diagnosed smear-positive pulmonary tuberculosis patients were randomly divided into two groups. The RHSI group, 2SHR / 7HR in 1981, 2SHD / 7HD in D_I group, 9HRE in 1983, and 9HDE in D_III group, 133 cases were treated with full course of treatment. R_Ⅰ, D_Ⅰ group similar efficacy in the near future, but the long-term efficiency of the D group was worse than the R group, which may be related to the use of rifamycin crystal form and dosage form. 1983 group R, D group in the sputum negative conversion rate, empty closure rate, the total effective rate of the lesions are similar, and the follow-up of 2 years of sputum bacilli recurrence rate was no significant difference. Showed that rifadine need to use the effective crystal form and the appropriate dosage form in the amount of conventional rifampicin dose of 1/2 to achieve similar efficacy, and less side effects, low cost of treatment.